Schedule 13D ownership disclosure
THERAVANCE BIOPHARMA INC
Ordinary Share $0.00001 Par Value · CUSIP: G8807B106
Event date: 2026-03-23
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Weiss Asset Management LPReported CIK 0001357550
Shares: 7,457,060 · Class: 14.5%
- BIP GP LLCReported CIK 0001298983
Shares: 4,628,074 · Class: 9.0%
- WAM GP LLCReported CIK 0001504664
Shares: 7,457,060 · Class: 14.5%
- Andrew M. WeissReported CIK 0001357643
Shares: 7,457,060 · Class: 14.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-124073
- Form type
- SCHEDULE 13D/A
- Filer
- Theravance Biopharma, Inc.
- CIK
- CIK 1583107
- Filed
- Mar 25, 2026
- Reporting period
- Mar 23, 2026
- Description
- Schedule 13D beneficial ownership